The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government.
Read our disclaimer for details.
Immunogenicity [ Time Frame: maximum 5 years (100 exposure days) ]
Number of patients that develop an inhibitor
Secondary Outcome Measures :
Efficacy [ Time Frame: Maximum 5 years (100 exposure days) ]
Efficacy of human cl rhFVIII during prophylactic treatment (frequency of break thorugh blleds) Efficacy of human cl rhFVIII during treatment of bleeds (Number of injections needed to stop a bleed) Efficacy of human cl rhFVIII during surgical prophylaxis (compare expected estimated blood loss versus actual estimated blood loss)
Other Outcome Measures:
Safety and tolerability [ Time Frame: 5 years ]
Measure vital signs, Adverse events, and standard hematology and chemistry laboratory parameters. This assessment is descriptive)
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.
Ages Eligible for Study:
Child, Adult, Older Adult
Sexes Eligible for Study:
Accepts Healthy Volunteers:
Severe Hemophilia A (FVIII:C <1%)
No previous treatment with with FVIII concentrates or other blood prodcuts containing FVIII
Diagnosis with a coagulation disorder other than Hemophilia A
Severe liver or kidney disease
Concomitant treatment with any systemic immunosuppressive drug